Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDT in previously untreated multiple myeloma
NCT00523848Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jun 2006
- Primary completion
- Sep 2011
- Modality
- Modified Peptides, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, pegylated liposomal doxorubicin, thalidomide in multiple myeloma (MM), sponsored by Roswell Park Comprehensive Cancer Center. Started Jun 2006; status: completed.
02
Drugs
bortezomibpegylated liposomal doxorubicinthalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00523848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00523848.